24 results about "Tigecycline" patented technology

The invention discloses a new application of nitrofurantoin alone or in combination with tigecycline. The application refers to the application of nitrofurantoin alone or in combination with tigecycline in inhibition of tigecycline drug-resistant bacterium infection. According to the present invention, the single use of furantoin or the combination of furantoin and tigecycline provides strong antibacterial activity for lon gene mutation and tet (X4) mediated tigecycline drug-resistant bacteria, and the furantoin single use or the combination of furantoin and tigecycline can enhance the survival rate of greater wax moths, the colonization of the tet (X4)-mediated tigecycline drug-resistant bacteria in mouse organs can be effectively reduced, and the healing of skin wound infection caused by tet (X4)-mediated tigecycline drug-resistant bacteria can be remarkably promoted by the combined medication. Furantoin designed depending on interaction sensitivity and tigecycline combined medication can be used for resisting tigecycline drug-resistant pathogens and treating diseases caused by tigecycline drug-resistant bacterium infection, and meanwhile, the evolution of tigecycline drug resistance can be prevented.

The invention relates to the technical field of molecular diagnosis technology, in particular to a method for detecting tigecycline resistance of klebsiella pneumoniae by mutation detection and application of the method. The method comprises the following steps: firstly, sampling a sample, adding a lysis solution containing a specific lysis enhancer, incubating at 37 DEG C, and then carrying out gradient centrifugation to take a supernatant; then extracting nucleic acid by using special bifunctional magnetic nanoparticles, washing and then eluting; preparing a PCR reaction system containing primers, enzyme and the like, and adding a novel auxiliary factor for amplification; then detecting mutation by using a compound nucleic acid dye through an HRM (High Resolution Melting) technology; and finally, comparing melting curves, and combining a machine learning algorithm to judge whether the sample is drug-resistant. The detection method has outstanding advantages; the innovative steps of sample treatment, nucleic acid extraction and detection improve the detection accuracy and efficiency, and can accurately identify low-level drug-resistant strains; meanwhile, the cost is greatly reduced, popularization in primary hospitals is facilitated, and great significance on prevention and control of drug-resistant bacteria is achieved.

The invention discloses a tigecycline microsphere preparation process, and belongs to the technical field of medicines. The tigecycline injection is prepared from 40 g of tigecycline, 266 g of PLGA, 5.3 kg of PLGA, 5.4 kg of dimeticone, 205 kg of n-heptane, 24 kg of ethyl alcohol, 30 kg of n-heptane and 30 kg of n-heptane, high safety is achieved, large-scale production is easy, the stability and reproducibility of the preparation process are good, and the preparation price is reduced; the left receiving tank base and the right receiving tank base abut against each other through force application of the electric push rods on the two sides, the S-shaped elastic piece is clamped between the left tank cavity and the right tank cavity, the electric control magnetic force generator generates intermittent magnetic force to attract and release the stainless steel balls, and the main control motor drives the platform base to rotate. During use, ingredients stored in the first storage tank and the second storage tank enter the left tank cavity and the right tank cavity, due to rotation of the platform base, the left receiving tank base and the right receiving tank base rotate along with the platform base, the proportioning and mixing effects are achieved, and the S-shaped elastic piece is matched with the rusted steel balls, so that liquid materials are evenly mixed on the inner side of the tank body.

The invention discloses a preparation method of a tigecycline USP impurity G. The tigecycline USP impurity G is obtained by taking tigecycline as a raw material, adding an oxidizing agent metachloroperbenzoic acid, and carrying out oxidation rearrangement reaction, separation and purification. The invention discloses a method for preparing a tigecycline USP impurity G, and aims to provide a method for preparing the tigecycline USP impurity G. The purity of a target product obtained through the method is 95% or above, the target product can be directly used as a tigecycline impurity detection reference substance, specific economic benefits are generated, and the method has a good application prospect. Belongs to the technical field of medicine.

This invention belongs to the field of drug metabolism and analytical chemistry, specifically relating to a method for the rapid determination of tigustastat and its active metabolite GD-MET-1 concentrations in a human liver microsome incubation system using liquid chromatography-tandem mass spectrometry (LC-MS / MS). The method first prepares stock solutions of tigustastat, GD-MET-1, and an internal standard, and prepares a series of standard curve solutions, quality control solutions, and precipitant solutions containing the internal standard. Next, the sample with the added precipitant solution undergoes vortexing and centrifugation pretreatment. Finally, chromatographic and mass spectrometric conditions are set, and the analysis is performed by LC-MS / MS. This method has been validated for specificity, accuracy, precision, matrix effects, recovery, residues, and stability, and can be reliably used for metabolic stability studies of tigustastat and GD-MET-1 in a human liver microsome incubation system, GD-MET-1 formation studies, metabolic enzyme identification, enzyme kinetic studies, and drug interaction studies.

The present application relates to the new use of paclitaxel in the synergistic effect of the antibiotic action of tigecycline, and the use of paclitaxel in the preparation of a composition or a compound preparation for the synergistic effect of the antibiotic action of tigecycline, and the ratio of paclitaxel to tigecycline is between 16:1-256:1. In the present application, paclitaxel and tigecycline show significant synergistic effect, and the FICI is 0.1875-0.3125 (all less than 0.5), that is, the combination of the two shows significant synergistic effect. By using the combination of paclitaxel, the use amount of tigecycline can be effectively reduced, and the use amount of tigecycline alone is 1 to 16 times higher than that of the combination of paclitaxel and tigecycline.

The invention discloses a preparation method of nano bamboo charcoal for treating areca yellow leaf disease, and relates to the technical field of polymer modified materials. According to the method, a multifunctional slow-release system is constructed through a five-stage process; gradient pyrolysis and superfine grinding are adopted to prepare a bamboo charcoal precursor; (2) liquid nitrogen assisted ball milling is combined with hydrothermal activation to form nano bamboo charcoal with a specific surface area, and a 2-5nm mesoporous structure is synchronously constructed; (3) surface charge regulation and control are realized through polyethyleneimine grafting and sodium hexachloroiridate loading, and the antibacterial activity is enhanced; (4) coating the tigecycline-bamboo charcoal complex with mesoporous silica to form a 20-30nm slow-release unit, so as to realize targeted drug release; and (5) preparing stable suspension through high-pressure homogenization. The technology provides an efficient and environment-friendly solution for areca yellow leaf disease treatment, and has the functions of soil remediation and plant health care.

The invention discloses aroma-like fungi C8-3 and an application of the aroma-like fungi C8-3 in degradation of tetracycline antibiotics. The strain is preserved in Guangdong Microbial Culture Collection Center on May 12, 2025, and the preservation number is GDMCC 66301. The C8-3 strain is a novel aroma-like fungus strain, has unique genome and physiological and biochemical characteristics, can significantly degrade tetracycline antibiotics, such as tetracycline (P = 0.0015), doxycycline (P < 0.0001) and tigecycline (P < 0.0001), especially can degrade (67.8 + / -2.4)% of tetracycline within 24 h, and has a good application prospect in the field of tetracycline drug microbial degradation.

The invention relates to a molecular marker of drug-resistant mycobacterium abscessus based on fusA gene mutation and application of the molecular marker, and belongs to the technical field of biological medicines. The invention provides a group of molecular markers for detecting the drug resistance of mycobacterium abscessus. The molecular markers are mutations on a fusA gene of the mycobacterium abscessus, including fusA1318Agt; g, fusA 1613 G gt; a, fusA18721883 dup GGGCGACGTGAT, and the number of the GGGCGACGTGAT is 1: 1. The invention finds that when the mycobacterium abscessus generates fusA1613 G gt; when A is mutated, cross resistance is generated to aminoglycoside drugs, macrolide drugs and tetracycline drug tigecycline. The fusA < 1318 > A < gt > is generated; the mycobacterium abscessus with mutations of G and fusA18721883 dup GGGCGACGTGAT is resistant to aminoglycoside drugs and tigecycline, and meanwhile, the mycobacterium abscessus has lateral sensitivity to macrolide drugs. The mycobacterium abscessus with mutations of G and fusA18721883 dup GGGCGACGTGAT is resistant to aminoglycoside drugs and tigecycline. The method is of great significance to clinical molecular diagnosis and medication.

The present application relates to a new use of curcumin in synergistic tigecycline antibacterial effect. The use amount of curcumin is 32 μg / mL-128 μg / mL, and the use amount of tigecycline is 0.015-4 μg / mL. In the preparation of composition or compound preparation, when curcumin is used to synergize the antibacterial effect of tetracycline antibiotic tigecycline, the ratio of the use amount of curcumin to tigecycline is between 8:1-8533:1. The present application can restore the sensitivity of drug-resistant bacteria to tigecycline, reduce the dosage of tigecycline, improve the antibacterial treatment effect, reduce the toxic side effects, and has important clinical application value.

The invention discloses a Ts-ELP temperature-sensitive self-assembly nano fusion protein, an antibiotic delivery system and a preparation method, and belongs to the technical field of nano preparations. The fusion protein comprises antibacterial peptide Ts and elastin-like polypeptide ELP which are sequentially connected. An MMP-9 restriction enzyme cutting site is introduced between the antibacterial peptide Ts and the elastin-like polypeptide ELP. Fusion protein and tigecycline (Tig) are self-assembled to form an antibiotic delivery system, the delivery system has Gram-negative bacterium surface lipopolysaccharide targeted recognition capability, and drug release is triggered through pH response and a phase separation mechanism in an infection microenvironment, so that the enrichment efficiency of tigecycline in a focus area is enhanced, and the drug delivery efficiency is improved. The antibiotic delivery system has the technical advantages of strong targeting property, enhanced antibacterial activity, low drug-resistant induction risk, good biological safety, simple preparation process, high yield and the like, can be used for treatment of multi-drug-resistant bacterium infection, and is especially suitable for prevention and treatment of carbapenem-resistant klebsiella pneumoniae (CRKP) and drug-resistant gram-negative bacterium infection related diseases.

The invention relates to the technical field of drug resistance gene detection. The invention provides a primer probe group for detecting tigecycline drug-resistant genes and a detection method thereof. The primer probe group comprises a primer probe group of tet (X3) genes and / or a primer probe group of tet (X4). The recombinase-mediated isothermal nucleic acid amplification detection method for the drug-resistant genes tet (X3) and tet (X4), established by the invention, has the remarkable advantages of short consumed time (only 21min), strong specificity, good sensitivity and strong stability, can effectively improve the accuracy and efficiency of clinical diagnosis, and overcomes the defects that the traditional gene detection methods such as PCR (Polymerase Chain Reaction) are long in consumed time, need for multiple times of cyclic amplification detection, and are low in detection efficiency. And more reliable means and basis are provided for clinical diagnosis. In addition, the method is simple to operate and easy to popularize and apply, and has great popularization value and application prospect for clinical work.

The present invention discloses the application of a hinokitiol composition in the preparation of a Staphylococcus aureus inhibitor. After adding hinokitiol, the survival rate of Staphylococcus aureus drug-resistant bacteria significantly decreases when treated with tetracycline, tigecycline, and chlortetracycline, indicating that these two substances can improve the sensitivity of Staphylococcus aureus drug-resistant bacteria to tetracycline, tigecycline, and chlortetracycline and have a synergistic effect. Animal experiments show that the combination of hinokitiol and tetracycline can significantly reduce the Staphylococcus aureus load colonized in the nasal cavity of mice. The hinokitiol provided by the present invention can be combined with tetracycline antibiotics to have a strong synergistic antibacterial effect both in vivo and in vitro, providing a brand-new technical method for the prevention and treatment of diseases in humans and farm animals.

The invention relates to the technical field of biological medicines, and discloses preparation and application of targeted gram-negative bacterium-resistant bionic dual-modified nanoparticles. Comprising the following steps: S1, synthesis of GBP1c peptide; S2, preparation of PLGA / tigecycline nanoparticles; S3, preparation of GBP1c modified PLGA / tigecycline nanoparticles; S4, preparation of GBP1c-neobaicalein dual modified PLGA / tigecycline nanoparticles; according to the invention, through functional linkage of the GBP1c peptide, the neobaicalein and the macrophage membrane, a synergistic system of targeting anchoring, drug resistance antagonism and inflammation chemotaxis is constructed. The GBP1c peptide is specifically combined with Gram-negative bacterium outer membrane lipopolysaccharide by virtue of a multi-basic amino acid sequence to realize accurate targeting, NEO synchronously blocks LPS transport to destroy the bacterium outer membrane and inhibit a P-glycoprotein efflux pump to prolong drug retention, and MM guides nanoparticles to enrich an infected part by virtue of inflammation chemotactic characteristics, so that the drug retention is prolonged. The three are linked to solve the core problems of poor DDS targeting and insufficient drug permeation in the prior art.

The invention discloses a phthalylhydrazine derivative functionalized chemiluminescent gold nanocluster and a preparation method thereof. The chemiluminescent gold nanocluster is prepared by taking a phthalylhydrazine derivative as a reducing agent and a ligand through a water phase reduction method. The gold nanocluster acts with potassium persulfate to generate a stable and high-intensity chemiluminescence signal. The invention has the characteristics of simple preparation method, mild reaction conditions, good reproducibility, strong chemiluminescence signal and the like. On the basis of coordination between tigecycline molecules and gold nanoclusters, electron distribution and excited state energy level structures of the gold nanoclusters are changed, so that the chemiluminescence performance of the gold nanoclusters is regulated and controlled, and high-sensitivity chemiluminescence detection of tigecycline is realized. The chemiluminescent probe has important application value in the field of biological medicine analysis.

The present invention provides a tetracycline antibiotic synergist and its application in drug-resistant Escherichia coli, belonging to the field of medical technology. Specifically, α-terpineol is used as a synergist in combination with tetracycline antibiotics to fight against drug-resistant Enterobacter. Experiments show that α-terpineol can effectively enhance the sensitivity of tetracycline antibiotics tigecycline / doxycycline to drug-resistant Enterobacter. The combined use of α-terpineol and tigecycline / doxycycline can significantly reduce the minimum inhibitory concentration of tigecycline / doxycycline in the combined combination, which can effectively improve the efficacy of the above-mentioned antibiotics against drug-resistant Enterobacter, and achieve the purpose of reducing the dosage of antibiotics, which is of great significance for solving clinical drug-resistant Escherichia coli infections. The present invention provides technical support for the treatment and control of drug-resistant Enterobacter in clinical practice.

The present application relates to a kind of continuous evolution system based on T7 RNA polymerase mutant and its application, belong to the technical field of evolutionary engineering.The present application is based on the T7 RNA polymerase mutant with the ability of synthesizing single-stranded DNA, constructs the continuous evolution system comprising single-stranded DNA synthesis template and T7 RNA polymerase mutant, the continuous evolution system is introduced into host, T7 RNA polymerase mutant is recombined with target gene by synthesizing single-stranded DNA, so that host is constructed to obtain mutant library in the process of continuous passage, host is subjected to screening pressure, and host realizes continuous evolution.The system is applied to complete the evolution of tetracycline efflux pump protein in 7 days, and the tryptophan deficiency of saccharomyces cerevisiae is repaired in 24 hours.The tetracycline efflux pump protein mutant screened can tolerate tetracycline and tigecycline, and the tolerance to tigecycline is increased by 8 times, and the tolerance to tetracycline is increased by 2 times, which is of great significance to improve the performance of cell factory.

The invention discloses an application of cinacalcet hydrochloride in preparation of drugs for resisting drug-resistant bacteria. The invention finds that the cinacalcet hydrochloride (CC) has dual effects, on one hand, the sensitivity of a strain carrying a tmexCD-toprJ gene cluster to tigecycline can be recovered, and on the other hand, the conjugational metastasis of antibiotic resistance genes can be inhibited by reducing over 99% of plasmid propagation. The synergistic effect of the CC and the tigecycline is that the minimum inhibitory concentration of the tigecycline is reduced by at least 8 times by dissipating proton dynamic potential and inducing active oxygen to damage an excretion function. Besides, the CC also reduces propagation of various drug-resistant plasmids by synergistically inhibiting expression of an Mpf and Dtr conjugation system and inhibiting SOS response, so that plasmid transfer and stable colonization of exogenous DNA (Deoxyribose Nucleic Acid) are blocked. The CC overcomes the tigecycline drug resistance mediated by tmexCD-topJ by destroying energy metabolism and oxidative stress, and meanwhile, limits horizontal transfer of other drug-resistant genes.

The invention relates to a continuous evolution system based on a T7RNA polymerase mutant and application of the continuous evolution system, and belongs to the technical field of evolution engineering. The method comprises the following steps: on the basis of a T7RNA polymerase mutant with a single-stranded DNA synthesis capability, constructing a continuous evolution system containing a single-stranded DNA synthesis template and the T7RNA polymerase mutant, introducing the continuous evolution system into a host, and recombining the T7RNA polymerase mutant with a target gene by synthesizing single-stranded DNA, so that the host constructs a mutant library in a continuous passage process, screening pressure is applied to the host, and the host realizes continuous evolution. By applying the system, evolution of tetracycline efflux pump protein is completed within 7 days, the tryptophan defect of saccharomyces cerevisiae is repaired within 24 hours, the tetracycline efflux pump protein mutant obtained through screening can tolerate tetracycline and tigecycline, the tolerance to the tigecycline is increased by 8 times, the tolerance to the tetracycline is increased by 2 times, and the tetracycline efflux pump protein mutant has the advantages that the tetracycline efflux pump protein mutant can tolerate the tetracycline and the tigecycline. The important significance is realized on improving the cell factory performance.

The present invention includes novel molecules and methods for using the same to treat Alcohol Use Disorder (AUD), Substance Use Disorder (SUD), tobacco use, pain, or proinflammatory disorders comprising: identifying a subject in need of treatment for at least one of AUD, SUD, pain, or a proinflammatory disorder; and providing the subject with an effective amount of a modified minocycline to ameliorate or eliminate the AUD, SUD, pain, or proinflammatory disorder and that has reduced, or no, antimicrobial activity, wherein the modified tetracycline has a formula, e.g., or the modified doxycycline, minocycline, and tigecycline and their tautomerized structures, where the R-groups shown in the minocycline example above could be different combination of halogen, acetyl ester, methyl ester, and diacetal.

The invention relates to a novel application of paclitaxel in enhancing the antibacterial effect of tigecycline antibiotics. When the composition or the compound preparation is prepared, paclitaxel is used for enhancing the antibacterial effect of tigecycline, and the dosage ratio of paclitaxel to tigecycline is (16: 1)-(256: 1). The paclitaxel and the tigecycline are combined to show a remarkable synergistic effect, and the FICI is 0.1875-0.3125 (both less than 0.5), namely the paclitaxel and the tigecycline are combined to show the remarkable synergistic effect. The use amount of tigecycline can be effectively reduced by using the combined paclitaxel, and the use amount of tigecycline independently used is 1-16 times higher than that of the combined use of paclitaxel and tigecycline.

The invention discloses a fragrance-like fungus C15-4 strain and an application of the fragrance-like fungus C15-4 strain. The strain is preserved in Guangdong Microbial Culture Collection Center on May 9, 2025, and the preservation number is GDMCC 66292. The C15-4 strain is a novel aroma-like bacterium, is different from the existing aroma-like bacterium strain in the aspects of genome and physiological and biochemical characteristics, has the capability of efficiently degrading tetracycline antibiotics, can obviously degrade tetracycline (P = 0.0004), doxycycline (P = 0.0004) and tigecycline (P = 0.0002) within 24 hours, has the tetracycline degradation rate of (69.6 + / -3.9)%, and has the advantages that the tetracycline (P = 0.0004), doxycycline (P = 0.0004) and tigecycline (P = 0.0002) can be effectively degraded; the method has a good application prospect in the aspect of degrading residual tetracyclic antibiotics in the environment.

The application belongs to the technical field of biological medicine, and provides application of ferulic acid in preparation of a photolysis inhibitor of tigecycline and minocycline. The ferulic acid can significantly inhibit degradation of tigecycline or minocycline under light conditions, and further enhance the antibacterial activity of tigecycline or minocycline under light conditions. Compared with the treatment of tigecycline alone, the addition of ferulic acid can significantly enhance the treatment effect of tigecycline or minocycline as an external medicine on skin or soft tissue infection, effectively expand the drug dosage form of tigecycline or minocycline, and provide a safer and more reliable drug preparation for the treatment of complex drug-resistant pathogenic bacterial skin or soft tissue infection.

Described herein is a composition comprising a micronized tigecycline having a Dv90 mean particle size of less than 7 μm, wherein the composition is a powder, wherein the composition is carrier free, and wherein the composition is free of any stabilizing excipients. Also, described herein is a method of treating a pulmonary infection in a subject, comprising administering to a subject a composition of micronized tigecycline. The composition can be administered by means of local delivery, pulmonary delivery, or inhaled delivery.